Quality by Design in Pharmaceuticals: Enhancing Product Development and Regulatory Compliance

Yogitha Chilaka — 2026-04-27

Quality by Design represents a methodical and scientific strategy in pharmaceutical development, emphasizing the integration of quality into products from the outset instead of depending exclusively on testing the final product. This article highlights the key principles of Quality by Design (QbD), which include creating a Quality Target Product Profile (QTPP) and identifying Critical Quality Attributes (CQAs) and using risk assessment tools to ensure product consistency and safety. It also emphasizes the significance of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) in affecting product quality. Advanced techniques such as Design of Experiments (DoE) and Process Analytical Technology (PAT) are discussed to optimize formulations and assist real-time observation throughout the manufacturing process. The concept of design space along with the formulation of efficient control strategies are highlighted as essential components for attaining regulatory flexibility and reliable processes. Additionally, the article examines the utilization of Quality by Design (QbD) in product development and manufacturing, analytical method development, and lifecycle management. Overall, QbD enhances product quality, reduces variability, minimizes failures, and supports continuous improvement, making it a vital approach in modern pharmaceutical industries.

LC-MS Based Bioanalytical Techniques for Quantitative Estimation of Drugs Recent Advances and Regulatory Perspectives

Harini Mukkala — 2026-04-28

Conventional bioanalytical techniques like, high-performance liquid chromatography with ultraviolet or fluorescence detection, have long been used for drug quantification. However, these approaches had historically faced various limitations in sensitivity, selectivity, and reliability when applied to the quantitative estimation of drugs in complex biological matrices. These challenges included inadequate assessment of trace level analytes, interference from endogenous matrix constituents, in addition these methods also struggle to differentiate structurally related compounds, including metabolites and isomers, resulting in compromised accuracy. Collectively, these challenges have posed significant obstacles in pharmacokinetic, bioavailability, and bioequivalence studies, where precise and reproducible measurements are critical.

The introduction of liquid chromatography -mass spectroscopy (LC-MS) based bioanalytical techniques has substantially overcome these limitations. By integrating advanced chromatographic separation with high-sensitivity mass spectroscopy (LC-MS) enables the precise quantification of drugs and their metabolites even at minute levels. It offers high selectivity by identifying compounds based on their mass-to-charge ratio, which helps to reduce interference from other substances present in biological samples.

This study is carried out to provide a comprehensive understanding of LC-MS based bioanalytical techniques that are used in quantitative estimation of drugs in biological matrices. Due to increasing demand for highly sensitive, selective, and rapid analytical methods in pharmaceutical and clinical research, LC-MS has become an essential and indispensable asset.

Journal of Innovations in Applied Pharmaceutical Science (JIAPS)

Quality by Design in Pharmaceuticals: Enhancing Product Development and Regulatory Compliance

LC-MS Based Bioanalytical Techniques for Quantitative Estimation of Drugs Recent Advances and Regulatory Perspectives